Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
暂无分享，去创建一个
R. Collins | P. Greenberg | G. Gaidano | S. Kambhampati | H. Kantarjian | G. Garcia-Manero | E. Jabbour | D. Steensma | P. Fenaux | K. Kreuzer | M. Sekeres | G. Roboz | U. Platzbecker | M. Baer | L. Godley | N. Azarnia | A. Al-Kali | F. Wilhelm | B. Scott | L. Silverman | E. Atallah